- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
On Weed, U.K. Government Ignores Scientific Advice
25 November 2008 2:16 pm
Today, the U.K. Parliament's House of Lords approved the government's proposal to reclassify cannabis as a dangerous Class B drug, along with amphetamines and speed, against the recommendations of its own Advisory Council on the Misuse of Drugs (ACMD). Cannabis had been classified previously as a class C drug, one of those the government deems least likely to cause harm.
The vote prompted an angry reaction from high-profile members of the U.K. scientific community.
In a letter to the Guardian, the scientists wrote that "the ACMD clearly recommended—for the third time in the last six years—that cannabis remains a class C drug, and did so after examining all the available and latest evidence on short- and long-term health risks, as well as social harms, public attitudes and policing priorities.” The recommendations of the ACMD report, prepared at the request of the Home Office, argue against "greater criminalisation of possession," the letter says.
The scientists also warn about dangers to the drug classification system’s credibility: "Reclassification would send out an ambiguous message about the dangers of current class B drugs." Signatories of the letter include David King and Robert May, former government chief scientific advisers; Colin Blakemore, a member of the U.K. Drug Policy Commission and former director of the Medical Research Council; and Gabriel Horn, chair of the Academy of Medical Sciences Working Group on Brain Science, Addiction and Drugs.